Regeneron Pharmaceuticals Inc. buy PapaSmurf
Summary
This prediction ended on 19.12.19 with a price of €335.35. The prediction had a final performance of 25.13%. PapaSmurf has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Regeneron Pharmaceuticals Inc. | -3.156% | -3.156% | 47.282% | 95.361% |
iShares Core DAX® | -0.116% | 1.953% | 14.155% | 16.268% |
iShares Nasdaq 100 | -2.733% | -1.273% | 31.828% | 43.377% |
iShares Nikkei 225® | -1.721% | 3.263% | 12.922% | 8.501% |
iShares S&P 500 | -1.527% | 0.194% | 27.117% | 41.752% |
Comments by PapaSmurf for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren